Schrodinger affirms FY25 guidance

The company states: “As of May 7, 2025, Schrodinger (SDGR) maintained its previously issued financial guidance for the fiscal year ending December 31, 2025: Software revenue growth is expected to range from 10% to 15%. Drug discovery revenue is expected to range from $45 million to $50 million. Software gross margin is expected to range from 74% to 75%. Operating expense growth in 2025 is expected to be less than 5%. Cash used for operating activities in 2025 is expected to be significantly lower than cash used for operating activities in 2024. For the second quarter of 2025, software revenue is expected to range from $38 million to $42 million.”